Momenta Pharmaceuticals to Present at 9th Annual MASS Opportunities Investment Conference
CAMBRIDGE, Mass., Oct. 31, 2007 (PRIME NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P. Shea, Chief Financial Officer, will deliver a corporate presentation at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 3:20 p.m. EST. The conference will be held at the Hilton Logan Airport in Boston, MA.
A live audio webcast of each presentation will be available on the “Investors” section of the Company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through December 8, 2007.
About Momenta
Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products as well as to the discovery and development of novel drugs. The Company’s most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta’s first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company’s discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars’ functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley, Investor Relations 617-395-5189